Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M106Revenue (TTM) $M--Net Margin (%)--Altman Z-Score10.8
Enterprise Value $M78.0EPS (TTM) $-0.4Operating Margin %--Piotroski F-Score3
P/E(ttm)--Beneish M-Score-4.6Pre-tax Margin (%)--Higher ROA y-yN
Price/Book4.210-y EBITDA Growth Rate %--Quick Ratio8.5Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio8.5Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-50.0Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-53.5Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M46.1ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with PTIE

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
PTIECharles Brandes 2016-03-31 Add$1.6 - $2.23
($1.84)
$ 2.3025%Add 107.92%37,719
PTIECharles Brandes 2015-12-31 Reduce$1.75 - $2
($1.89)
$ 2.3022%Reduce -4.20%18,141
PTIEGeorge Soros 2015-09-30 Sold Out $1.69 - $1.99
($1.8)
$ 2.3028%Sold Out0
PTIECharles Brandes 2015-09-30 Buy $1.69 - $1.99
($1.8)
$ 2.3028%New holding18,937
PTIEMario Gabelli 2015-06-30 Reduce$1.65 - $2.62
($1.96)
$ 2.3017%Reduce -7.14%65,000
PTIEGeorge Soros 2015-06-30 Buy $1.65 - $2.62
($1.96)
$ 2.3017%New holding21,700
PTIEMario Gabelli 2015-03-31 Reduce$1.66 - $2.12
($1.93)
$ 2.3019%Reduce -17.65%70,000
PTIEMario Gabelli 2014-09-30 Reduce$3.6 - $5.72
($4.32)
$ 2.30-47%Reduce -33.33%100,000
PTIEFirst Eagle Investment 2014-06-30 Add0.01%$4.58 - $6.06
($5.28)
$ 2.30-56%Add 22.14%4,474,735
PTIEGeorge Soros 2014-06-30 Sold Out -0.01%$4.58 - $6.06
($5.28)
$ 2.30-56%Sold Out0
PTIEFirst Eagle Investment 2014-03-31 Add0.01%$3.92 - $5.71
($5.03)
$ 2.30-54%Add 25.15%3,663,750
PTIEGeorge Soros 2014-03-31 Buy 0.01%$3.92 - $5.71
($5.03)
$ 2.30-54%New holding103,700
PTIEFirst Eagle Investment 2013-12-31 Add0.01%$2.61 - $4.73
($3.79)
$ 2.30-39%Add 20.37%2,927,386
PTIEMario Gabelli 2013-12-31 Reduce$2.61 - $4.73
($3.79)
$ 2.30-39%Reduce -24.00%190,000
PTIEFirst Eagle Investment 2013-09-30 Add$2.21 - $3.11
($2.5)
$ 2.30-8%Add 30.60%2,431,935
PTIEFirst Eagle Investment 2013-06-30 Add0.01%$2.21 - $5.41
($3.02)
$ 2.30-24%Add 171.01%1,862,099
PTIEFirst Eagle Investment 2013-03-31 Add$2.47 - $3.74
($3.01)
$ 2.30-24%Add 30.53%687,099
PTIEFirst Eagle Investment 2012-12-31 Add$2.42 - $5.83
($3.66)
$ 2.30-37%Add 163.20%526,408
PTIEFirst Eagle Investment 2012-09-30 Buy $3.57 - $5.29
($4.22)
$ 2.30-45%New holding200,000
PTIEMario Gabelli 2011-03-31 Reduce-0.04%$6.05 - $9.72
($7.13)
$ 2.30-68%Reduce -53.97%480,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

PTIE is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


PTIE: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ROBERTSON SANFORDDirector 2013-11-06Buy50,000$3.73-38.34view
FRIEDMANN NADAVCOO 2011-10-18Sell25,000$4.44-48.2view
FRIEDMANN NADAVCOO 2011-10-04Sell25,000$4.81-52.18view
Sabretooth Master Fund, L.P.10% Owner 2011-10-04Sell382,000$4.59-49.89view
FRIEDMANN NADAVCOO 2011-09-15Sell25,000$4.89-52.97view
Sabretooth Master Fund, L.P.10% Owner 2011-08-08Sell44,417$4.2-45.24view
BARBIER REMICEO, Chairman of the Board, 10% Owner 2011-08-08Buy5,000$4.22-45.5view
BARBIER REMICEO & Chairman of the Board, 10% Owner 2010-10-04Sell50,000$6.2-62.9view
BARBIER REMICEO & Chairman of the Board, 10% Owner 2010-09-07Sell28,597$5.69-59.58view
BARBIER REMICEO & Chairman of the Board, 10% Owner 2010-09-02Sell21,403$5.81-60.41view

Quarterly/Annual Reports about PTIE:

News about PTIE:

Articles On GuruFocus.com
Wednesday Pre-Market Insights: GEVO, WPZ, HDP, PTIE May 13 2015 
Eveillard's First Eagle Increases 2 Positions Sep 11 2014 
Morning Coffee: Real-Time Picks May 14 2014 
Pain Therapeutics Reports Operating Results (10-K) Feb 03 2011 
Pain Therapeutics Reports Operating Results (10-Q) Oct 29 2010 
Pain Therapeutics (PTIE) CEO & Chairman of the Board, 10% Owner Remi Barbier sells 50,000 Shares Oct 04 2010 
Pain Therapeutics (PTIE) CEO & Chairman of the Board, 10% Owner Remi Barbier sells 28,597 Shares Sep 08 2010 
Pain Therapeutics (ptie) CEO & Chairman of the Board, 10% Owner Remi Barbier sells 21,403 Shares Sep 02 2010 
Pain Therapeutics (PTIE) CEO & Chairman of the Board, 10% Owner Remi Barbier sells 22,391 Shares Aug 04 2010 
Pain Therapeutics Reports Operating Results (10-Q) Jul 29 2010 

More From Other Websites
Pain Therapeutics Announces FDA Advisory Committee Meeting for REMOXY® May 19 2016
DURECT Announces FDA Advisory Committee Meeting for REMOXY® May 19 2016
Pain Therapeutics Announces FDA Advisory Committee Meeting for REMOXY® May 19 2016
PAIN THERAPEUTICS INC Financials May 17 2016
PAIN THERAPEUTICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 12 2016
Pain Therapeutics to Present New REMOXY Data At American Pain Society Meeting May 11 2016
DURECT Announces New REMOXY® Data being Presented at American Pain Society Meeting May 11 2016
DRRX: Update on First Quarter Financials May 06 2016
Pain Therapeutics reports 1Q loss May 05 2016
Pain Therapeutics reports 1Q loss May 05 2016
Pain Therapeutics Reports Q1 2016 Financial Results May 05 2016
PAIN THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 05 2016
Pain Therapeutics Reports Q1 2016 Financial Results May 05 2016
Pain Therapeutics Gains 7%, FDA Has Accepted Company's Remoxy For Review Apr 13 2016
DURECT Announces FDA Acceptance of REMOXY® NDA, PDUFA Date of September 25, 2016 Apr 12 2016
FDA Accepts REMOXY NDA for Review, Sets PDUFA Date of September 25, 2016 Apr 12 2016
PAIN THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 12 2016
FDA Accepts REMOXY NDA for Review, Sets PDUFA Date of September 25, 2016 Apr 12 2016
DRRX: REMOXY® NDA Resubmitted Mar 30 2016
DURECT Announces Resubmission of REMOXY® New Drug Application to the U.S. Food and Drug... Mar 29 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)